Department of Orthopaedic Surgery, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi City, Osaka 570-8506, Japan.
J Bone Joint Surg Am. 2010 Dec 1;92(17):2776-84. doi: 10.2106/JBJS.I.01325.
Bone marrow cells possess multipotentiality and have been used for several treatments. We hypothesized that bone marrow cells might differentiate into regenerated tendon and that several cytokines within bone marrow cells might accelerate tendon healing. Therefore, we treated Achilles tendon ruptures in a rat model with transplantation of whole bone marrow cells.
Nine F344/Nslc (Fisher) rats were the source of bone marrow cells and mesenchymal stem cells as well as normal Achilles tendons. Eighty-seven Fisher rats were used for the experiments. The rats were divided into three groups: the BMC group (bone marrow cells injected around the tendon), the MSC group (mesenchymal stem cells injected around the tendon), and the non-treated control group (incision only). Outcome measures included mechanical testing, collagen immunohistochemistry, histological analysis, and reverse transcription-polymerase chain reaction to detect expression of transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF).
The ultimate failure load in the BMC group was significantly greater than that in the non-treated or the MSC group at seven days after incision (3.8 N vs. 0.9 N or 2.1 N, p < 0.016) and at fourteen days after incision (10.2 N vs. 6.1 N or 8.2 N, p < 0.016). The ultimate failure load in the BMC group at twenty-eight days after incision (33.8 N) was the same as that of normal tendon (34.8 N). The BMC group demonstrated stronger staining for type-III collagen at seven days after incision and stronger staining for type-I collagen at twenty-eight days than did the MSC group. Expression of TGF-β and VEGF in the BMC group was significantly increased compared with that in the other groups at four days after incision (TGF-β: 1.6 vs. 1.3 or 0.6, p < 0.01; VEGF: 1.7 vs. 1.1 or 0.9, p < 0.01).
Transplantation of whole bone marrow cells may be a better and more readily available treatment for Achilles tendon rupture than cultured mesenchymal stem cells.
骨髓细胞具有多能性，并已被用于多种治疗方法。我们假设骨髓细胞可能分化为再生的肌腱，并且骨髓细胞内的几种细胞因子可能加速肌腱愈合。因此，我们通过移植整个骨髓细胞来治疗大鼠模型中的跟腱断裂。
9 只 F344/Nslc（Fisher）大鼠是骨髓细胞和间充质干细胞以及正常跟腱的来源。87 只 Fisher 大鼠用于实验。大鼠分为三组：BMC 组（骨髓细胞注射到肌腱周围）、MSC 组（间充质干细胞注射到肌腱周围）和未治疗对照组（仅切口）。结果测量包括力学测试、胶原免疫组织化学、组织学分析和逆转录-聚合酶链反应，以检测转化生长因子-β（TGF-β）和血管内皮生长因子（VEGF）的表达。
在切口后 7 天，BMC 组的最终失效负载明显大于未治疗组或 MSC 组（3.8 N 对 0.9 N 或 2.1 N，p <0.016）和切口后 14 天（10.2 N 对 6.1 N 或 8.2 N，p <0.016）。在切口后 28 天，BMC 组的最终失效负载（33.8 N）与正常肌腱相同（34.8 N）。与 MSC 组相比，BMC 组在切口后 7 天对 III 型胶原的染色更强，在切口后 28 天对 I 型胶原的染色更强。与其他组相比，在切口后 4 天，BMC 组 TGF-β和 VEGF 的表达明显增加（TGF-β：1.6 对 1.3 或 0.6，p <0.01；VEGF：1.7 对 1.1 或 0.9，p <0.01）。
与培养的间充质干细胞相比，移植整个骨髓细胞可能是治疗跟腱断裂的更好、更易得的方法。
Zotero 插件